Aventis is in the early stages of a plan to consolidate marketing-communications duties for its worldwide brands, the company confirmed last week. The estimated $300 million global advertiser begins the process with oncology drugs Taxotere and Genasense. Companies affected are within Havas, IPG, WPP and Omnicom. Havas’ Euro RSCG has Lantus; IPG’s McCann-Erickson handles Allegra. Neither is immediately affected.
Get Adweek's Brand Marketing Daily Newsletter in your Inbox
Today's highs and lows of creativity